What's happening: Cell‑free PL‑display platform accelerates peptide screening ten‑fold

Researchers at the Innovation Center of NanoMedicine unveiled PL‑display, a cell‑free system that immobilizes individual peptides on magnetic beads, delivering more than ten‑fold efficiency gains versus traditional cell‑based displays. The method remains functional under high‑temperature, high‑salt and toxic‑protein conditions, broadening screening capabilities.

Also developing:

• •Sanofi’s rilzabrutinib receives orphan drug designation in Japan for IgG4‑related disease
• •Roche’s fenebrutinib shows positive Phase III results as first BTK inhibitor for relapsing and primary progressive multiple sclerosis (FENhance 1)
• •Lynk Pharmaceuticals announces positive Phase III topline data for zemprocitinib in moderate‑to‑severe atopic dermatitis
• •InnoCare Pharma’s next‑generation TRK inhibitor zurletrectinib receives priority review in China for pediatric solid tumors